<SEC-DOCUMENT>0001213900-23-074964.txt : 20230907
<SEC-HEADER>0001213900-23-074964.hdr.sgml : 20230907
<ACCEPTANCE-DATETIME>20230907160131
ACCESSION NUMBER:		0001213900-23-074964
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230907
FILED AS OF DATE:		20230907
DATE AS OF CHANGE:		20230907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		231242216

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea184847-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Report of Foreign Private Issuer<BR>
Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the month of September 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Form
40-F </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CONTENTS</U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 7, 2023, SciSparc
Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial
of its Proprietary SCI-110 for Tourette Syndrome.&rdquo; A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated
by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 7, 2023, the Company
issued a press release titled &ldquo;SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement,&rdquo;
announcing the receipt of a letter from the Nasdaq Stock Market LLC. A copy of this press release is furnished herewith as Exhibit 99.2
and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Report of Foreign Private Issuer on Form 6-K is incorporated
by reference into&nbsp;the Company&rsquo;s registration statements on Form F-3 (File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">333-269839</FONT></A>,
File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">333-266047</FONT></A>,
File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">333-233417</FONT></A>,
File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">333-248670</FONT></A>
and File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">333-255408</FONT></A>)
and on Form S-8 (File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">333-225773</FONT></A>)
filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 91%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea184847ex99-1_scisparc.htm" STYLE="-sec-extract: exhibit">Press release issued by SciSparc Ltd. dated September 7, 2023, titled &ldquo;SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome.&rdquo;</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea184847ex99-2_scisparc.htm" STYLE="-sec-extract: exhibit">Press release issued by SciSparc Ltd. dated September 7, 2023, titled &ldquo;SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 7, 2023</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea184847ex99-1_scisparc.htm
<DESCRIPTION>SCISPARC ANNOUNCES INITIATION OF RANDOMIZED PHASE IIB CLINICAL TRIAL OF ITS PROPRIETARY SCI-110 FOR TOURETTE SYNDROME
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Initiation
of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site</I></FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEL
AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (&quot;Company&quot; or &quot;SciSparc&quot;), a specialty
clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous
system, today announced the initiation of its Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome
(&ldquo;TS&rdquo;) at the Tel Aviv Sourasky Medical Center in Israel (&ldquo;Sourasky&rdquo;).</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial is based on the positive data results received from the single arm Yale School of Medicine study using SCI-110 for TS.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;The
initiation of our Phase IIb Clinical Trial at Sourasky, the Israeli site, is a major milestone towards commercializing our proprietary
SCI-110 for TS patients. TS in adults can be a debilitating disorder for which current treatments result in limited benefits. Encouraged
by the results seen in the Phase IIa study at Yale School of Medicine, we look forward to continuing clinical research of the treatment
regimen in this double-blind randomized trial,&quot; said SciSparc&rsquo;s Chief Executive Officer, Oz Adler. &quot;This is an important
area of growth for the Company, alongside the Company&rsquo;s other proprietary platforms, including SCI-110 in patients with Alzheimer&rsquo;s
disease and agitation and SCI-210 for children suffering from autism spectrum disorder.&quot;</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase IIb clinical trial will be conducted at three global leading centers of excellence: the Yale Child Study Center at the Yale School
of Medicine in Connecticut, USA, the Hannover Medical School in Hannover, Germany, and at the Tel Aviv Sourasky Medical Center in Israel.
The Company has already secured the Institutional Review Board approvals from all three clinical sites, the&nbsp;Israeli Ministry of
Health's approval for the clinical trial at Sourasky, and approval from the Federal Institute for Drugs and Medical Devices in Germany
for conducting the trial at the Hannover Medical School.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
objective of this clinical trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110
in adult patients (between 18 and 65 years of age) using a daily oral treatment. The patients will be randomized at a 1:1 ratio to receive
either SCI-110 or a SCI-110-matched placebo. The primary efficacy objective of the trial will be to assess tic severity change using
the Yale Global Tic Severity Scale, the most commonly used measure in clinical trials of this kind, as a continuous endpoint at week
12 and week 26 of the double-blind phase compared to baseline. The primary safety objective of the trial is to assess absolute and relative
frequencies of serious adverse events for the entire population and, separately, for the SCI-110 and placebo groups.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About&nbsp;SciSparc&nbsp;Ltd.
(Nasdaq: SPRC):</B></FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale
of hemp seeds oil-based products on the&nbsp;<FONT STYLE="color: blue"><U>Amazon.com</U></FONT>&nbsp;Marketplace.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements:</B></FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses
that the initiation of the Phase IIb Clinical Trial at Sourasky is a major milestone towards commercializing SCI-110 and continuation
of the clinical research of the treatment regimen in this double-blind randomized trial, that this is an important area of growth for
the Company, alongside the Company&rsquo;s other proprietary platforms. Historical results of scientific research and clinical and preclinical
trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because
such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements
in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties,
including those discussed under the heading &quot;Risk Factors&quot; in SciSparc's Annual Report on Form 20-F filed with the SEC on&nbsp;May
1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or otherwise.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Contact:<BR>
<FONT STYLE="color: blue"><U>IR@scisparc.com</U></FONT><BR>
Tel: +972-3-6167055</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea184847ex99-2_scisparc.htm
<DESCRIPTION>SCISPARC GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID REQUIREMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.2</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Immediate Effect on Nasdaq Listing or Trading of the Company&rsquo;s Ordinary Shares</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEL
AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (&quot;Company&quot; or &quot;SciSparc&quot;), a specialty
clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous
system, today announced that it has received a notification letter from Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) that the Company
has been granted an additional 180-day compliance period, or until March 4, 2024 to regain compliance with Nasdaq&rsquo;s minimum bid
price rule.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq&rsquo;s
determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other
applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company&rsquo;s
written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse stock
split.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a notification letter dated March 8, 2023, Nasdaq had informed the Company that, based on the previous 30 consecutive business days,
the Company&rsquo;s ordinary shares no longer met the minimum $1.00 bid price per share requirement. Therefore, in accordance with Nasdaq&rsquo;s
Listing Rules, the Company was provided 180 calendar days, or until September 5, 2023, to regain compliance.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
at any time before March 4, 2024, the closing bid price of the Company&rsquo;s ordinary shares is at least $1.00 per share for a minimum
of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
current notification from Nasdaq has no immediate effect on the listing or trading of the Company&rsquo;s ordinary shares, which will
continue to trade on the Nasdaq Capital Market under the symbol &ldquo;SPRC.&rdquo;</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About&nbsp;SciSparc&nbsp;Ltd.
(Nasdaq: SPRC):</B></FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale
of hemp seeds oil-based products on the Amazon.com Marketplace.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements:</B></FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses
regaining compliance with Nasdaq&rsquo;s continued listing requirements, and the timing and effect thereof as well as potentially effecting
a reverse stock split. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions
of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and
are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the
heading &quot;Risk Factors&quot; in SciSparc's Annual Report on Form 20-F filed with the SEC on&nbsp;May 1, 2023, and in subsequent filings
with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation
to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information,
future events or circumstances or otherwise.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Contact:<BR>
<FONT STYLE="color: blue"><U>IR@scisparc.com</U></FONT><BR>
Tel: +972-3-6167055</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
